Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $65.750 |
Close | $64.960 |
Volume / Avg. | 730.757K / 974.063K |
Day Range | 64.920 - 66.710 |
52 Wk Range | 45.500 - 84.890 |
Market Cap | $6.858B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 39 |
Short Interest | 3.9% |
Days to Cover | 6.95 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Needham on Wednesday, May 8, 2024. The analyst firm set a price target for 90.00 expecting ITCI to rise to within 12 months (a possible 38.55% upside). 37 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $64.96 last updated May 10, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q2 earnings are confirmed for Thursday, August 1, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.